This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): alpha-glucosidase, alglucosidase alfa, rhGAA, GZ419829
Description: Myozyme is recombinant human acid a-glucosidase. Myozyme is the name for the drug produced at a 160L capacity site, and Lumizyme is the name for the product from the 2000L capacity site (glycosylation of the protein is altered with the larger capacity production).
Deal Structure: In connection with its efforts to develop a product for the treatment of Pompe disease, Genzyme General previously entered into two joint ventures with Pharming Group N.Va - one for the development of the transgenically-derived product, and the other for the development of CHO-derived products. In August 2001, Pharming Group filed for receivership in order to seek protection from creditors. Thereafter, Genzyme General assumed full operational and financial responsibility for the development of CHO-derived products.
In 2006, Duke University was issued a U.S. patent relating to alpha-glucosidase. Genzyme holds an exclusive license to this patent under a technology and patent license agreement with Synpac (North Carolina) Inc. Genzyme began making milestone and royalty payments to Synpac on October 1, 2006 under this agreement. Myozyme. They are going to be 13.5% of sales in those territories where the patent is issued and 6.75% of sales elsewhere.
In December 2009, Genzyme and...See full deal structure in Biomedtracker
Partners: DRI Capital Inc.
Additional information available to subscribers only: